Leveraging SGLT2's unique expression in early-stage malignancy, we aim to address the limitations of current imaging modalities and provide a foundation for future strategies to improve tumor localization and margin assessment for early-stage lung cancers. This evidence concerns the gene SLC5A2 and neoplasm.